There are two major pathways, homology-directed repair (HDR) and nonhomologous end joining (NHEJ), involved in double-strand break (DSB) repair. Single-stranded oligodeoxyribonucleotide (ssODN)-mediated homologous recombination repair is commonly used for animal site-directed genome editing, with great scientific and practical value. To improve ssODN-mediated HDR efficiency in the pig genome, we investigated the effect and molecular mechanism of mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor PD0325901 on the HDR efficiency in porcine fetal fibroblasts (PFFs). The results showed that PD0325901 obviously increased the percentage of G and S phase cell populations and reduced the cell population ratio in the G phase of PFFs, and promoted the expression of HDR repair factor. At the optimal concentration of 250 nmol/L, PD0325901 increased the repair efficiency of ssODN-mediated GFP reporter vector by 58.8% and the directed editing efficiency of PFF DMD and ROSA26 locus by 48.16% and 17.64%, respectively. The results show that MEK inhibitor PD0325901 significantly promotes the efficiency of ssODN-mediated homologous-directed repair in the porcine genome, thus offering a new idea to generate genetically modified pigs more effectively.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.16288/j.yczz.18-294 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Quantitative Live Imaging Reveals Phase Dependency of PDAC Patient-Derived Organoids on ERK and AMPK Activity.
Cancer Sci
December 2024
Department of Molecular Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Patient-derived organoids represent a novel platform to recapitulate the cancer cells in the patient tissue. While cancer heterogeneity has been extensively studied by a number of omics approaches, little is known about the spatiotemporal kinase activity dynamics. Here we applied a live imaging approach to organoids derived from 10 pancreatic ductal adenocarcinoma (PDAC) patients to comprehensively understand their heterogeneous growth potential and drug responses.
View Article and Find Full Text PDFThe clinically relevant MEK inhibitor mirdametinib combined with D-cycloserine and prediction error disrupts fear memory in PTSD models.
Transl Psychiatry
December 2024
School of Psychological Sciences, College of Health and Medicine, University of Tasmania, Tasmania, TAS, Australia.
This study establishes mirdametinib as the first MEK inhibitor that can undergo clinical development for psychiatric indications such as post-traumatic stress disorder (PTSD). PTSD is characterized by persistent traumatic memories with limited effective treatment options. A body of evidence suggests that memory storage is dynamic and constantly updated through post-retrieval modification a process termed reconsolidation.
View Article and Find Full Text PDFImmune-related glycosylation genes based classification predicts prognosis and therapy options of osteosarcoma.
Gene
January 2025
Zhejiang University, Hangzhou, Zhejiang 310058, China; Department of Orthopedics, Musculoskeletal Tumor Center, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China. Electronic address:
Osteosarcoma is the most common primary bone malignancy, with a very poor prognosis. Aberrant glycosylation is close involvement in osteosarcoma. Accordingly, this study aimed at investigating the role of glycosylation genes in the prognosis and therapy options of osteosarcoma.
View Article and Find Full Text PDFMEK inhibitor PD0325901 upregulates CD34 expression in endothelial cells via inhibition of ERK phosphorylation.
Regen Ther
June 2024
Advanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Article Synopsis
- CD34-positive endothelial progenitor cells (EPCs) are important for promoting blood vessel growth and could be useful in treating ischemic diseases, but their numbers and quality decline due to various factors, prompting research into better generation methods.* -
- Researchers explored using chemical compounds, specifically PD0325901, a MEK inhibitor, to reprogram human umbilical vein endothelial cells (HUVECs) into CD34-positive cells, leading to a significant increase in CD34 expression.* -
- The findings indicate that PD0325901 primarily enhances CD34 expression by reducing ERK phosphorylation in endothelial cells, offering insights for improving regenerative therapies for blood flow-related conditions.*
A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in Caenorhabditis elegans.
Cancer Res Commun
September 2024
Department of Diagnostics and Intervention, Surgery, Umeå University, Umeå, Sweden.
Unlabelled: Oncogenic signaling through the MAPK/ERK pathway drives tumor progression in many cancers. Although targeted MAPK/ERK pathway inhibitors improve survival in selected patients, most tumors are resistant. New drugs could be identified in small-animal models that, unlike in vitro models, can address oral uptake, compound bioavailability, and toxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!